Claire-Audrey Y Bayan1, Adriana T Lopez1, Robyn D Gartrell2, Kimberly M Komatsubara2, Margaret Bogardus1, Nisha Rao2, Cynthia Chen1, Thomas D Hart3, Thomas Enzler2, Emanuelle M Rizk2, Jaya Sarin Pradhan4, Douglas K Marks2, Larisa J Geskin5, Yvonne M Saenger6. 1. Columbia University College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, 10032, USA. 2. Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA. 3. Columbia College, Columbia University, New York, NY, 10027, USA. 4. Department of Pathology, Columbia University Medical Center, New York, NY, 10032, USA. 5. Department of Dermatology, Columbia University Medical Center, New York, NY, 10032, USA. 6. Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA. yms4@cumc.columbia.edu.
Abstract
PURPOSE OF REVIEW: Oncolytic virotherapy is a new approach to the treatment of cancer and its success in the treatment of melanoma represents a breakthrough in cancer therapeutics. This paper provides a review of the current literature on the use of oncolytic viruses (OVs) in the treatment of melanoma. RECENT FINDINGS: Talimogene laherparepvec (T-VEC) is the first OV approved for the treatment of melanoma and presents new challenges as it enters the clinical setting. Several other OVs are at various stages of clinical and pre-clinical development for the treatment of melanoma. Reports from phase Ib-III clinical trials combining T-VEC with checkpoint blockade are encouraging and demonstrate potential added benefit of combination immunotherapy. OVs have recently emerged as a standard treatment option for patients with advanced melanoma. Several OVs and therapeutic combinations are in development. Immunooncolytic virotherapy combined with immune checkpoint inhibitors is promising for the treatment of advanced melanoma.
PURPOSE OF REVIEW: Oncolytic virotherapy is a new approach to the treatment of cancer and its success in the treatment of melanoma represents a breakthrough in cancer therapeutics. This paper provides a review of the current literature on the use of oncolytic viruses (OVs) in the treatment of melanoma. RECENT FINDINGS:Talimogenelaherparepvec (T-VEC) is the first OV approved for the treatment of melanoma and presents new challenges as it enters the clinical setting. Several other OVs are at various stages of clinical and pre-clinical development for the treatment of melanoma. Reports from phase Ib-III clinical trials combining T-VEC with checkpoint blockade are encouraging and demonstrate potential added benefit of combination immunotherapy. OVs have recently emerged as a standard treatment option for patients with advanced melanoma. Several OVs and therapeutic combinations are in development. Immunooncolytic virotherapy combined with immune checkpoint inhibitors is promising for the treatment of advanced melanoma.
Authors: Ravi D Rao; Shernan G Holtan; James N Ingle; Gary A Croghan; Lisa A Kottschade; Edward T Creagan; Judith S Kaur; Henry C Pitot; Svetomir N Markovic Journal: Cancer Date: 2006-01-15 Impact factor: 6.860
Authors: Francis J Burrows; Martin Gore; W Russell Smiley; Martha Y Kanemitsu; Douglas J Jolly; Susana B Read; Thomas Nicholas; Carol A Kruse Journal: Cancer Gene Ther Date: 2002-01 Impact factor: 5.987
Authors: Giulia Fulci; Laura Breymann; Davide Gianni; Kazuhiko Kurozomi; Sarah S Rhee; Jianhua Yu; Balveen Kaur; David N Louis; Ralph Weissleder; Michael A Caligiuri; E Antonio Chiocca Journal: Proc Natl Acad Sci U S A Date: 2006-08-14 Impact factor: 11.205
Authors: P Zajac; D Oertli; W Marti; M Adamina; M Bolli; U Guller; C Noppen; E Padovan; E Schultz-Thater; M Heberer; G Spagnoli Journal: Hum Gene Ther Date: 2003-11-01 Impact factor: 5.695
Authors: Zoë Blake; Robyn D Gartrell; Emanuelle M Rizk; Rolando Perez-Lorenzo; Stuart P Weisberg; Ines Simoes; Camden Esancy; Yichun Fu; Danielle R Davari; Luke Barker; Grace Finkel; Manas Mondal; Hanna E Minns; Samuel W Wang; Benjamin T Fullerton; Francisco Lozano; Codruta Chiuzan; Basil Horst; Yvonne M Saenger Journal: Cancer Immunol Immunother Date: 2022-01-09 Impact factor: 6.630
Authors: Dale Han; Alexander C J van Akkooi; Richard J Straker; Adrienne B Shannon; Giorgos C Karakousis; Lin Wang; Kevin B Kim; Douglas Reintgen Journal: Clin Exp Metastasis Date: 2021-05-07 Impact factor: 4.510